Lv5
978 积分 2021-01-28 加入
Trends in target novelty in oncology R&D
3天前
已完结
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor
30天前
已完结
Potent Uncompetitive Inhibitors of Nicotinamide N-Methyltransferase (NNMT) as In Vivo Chemical Probes
1个月前
已完结
Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT) with Enhanced Activity
1个月前
已完结
Comparative Analysis of Two NNMT Bisubstrate Inhibitors through Chemoproteomic Studies: Uncovering the Role of Unconventional SAM Analogue Moiety for Improved Selectivity
1个月前
已完结
Discovery and Development of a Small-Molecule Inhibitor Targeting the GAS41 YEATS Domain in Nonsmall Cell Lung Cancer
1个月前
已完结
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9
1个月前
已完结
Clinical development times for innovative drugs
1个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
1个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
1个月前
已完结
皖公网安备34019202002308
